Anti-ETAR autoantibodies are more prevalent in SLE-PAH patients than those without PAH, and they trigger inflammation, cell proliferation, and vasoconstriction, positively correlating with systolic PAP. Here, EDNRA is linked to pulmonary arterial hypertension.